Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark L Bagarazzi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Human Vaccines & Immunotherapeutics|September 21, 2013
Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteersMalissa C Diehl, Jessica C Lee, Stephen E Daniels, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2016
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical TrialsChristopher L Jenkins, Mark L Bagarazzi, Hans-Peter Kiem, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsMatthew P Morrow, Pablo Tebas, Jian Yan, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjectsJessica C Lee, Stanley Menacherry, Malissa C Diehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after ImmunotherapyMatthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Science Translational Medicine|October 12, 2012
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responsesMark L Bagarazzi, Jian Yan, Matthew P Morrow, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Human Vaccines & Immunotherapeutics|September 21, 2013
Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteersMalissa C Diehl, Jessica C Lee, Stephen E Daniels, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2016
Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical TrialsChristopher L Jenkins, Mark L Bagarazzi, Hans-Peter Kiem, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsMatthew P Morrow, Pablo Tebas, Jian Yan, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjectsJessica C Lee, Stanley Menacherry, Malissa C Diehl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after ImmunotherapyMatthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Science Translational Medicine|October 12, 2012
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responsesMark L Bagarazzi, Jian Yan, Matthew P Morrow, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Lancet (London, England)|September 21, 2015
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialCornelia L Trimble, Matthew P Morrow, Kimberly A Kraynyak, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Pageof 2